​​Lysosomal Therapeutics Inc.​​

Delivering cures for neurodegenerative diseases. 

Dimitri Krainc, M.D., Ph.D., Scientific Founder, Chairman of the Scientific Advisory Board. Dimitri is Aaron Montgomery Ward Professor of Neurology, Chairman of the Ruth and Ken Davee Department of Neurology at the Feinberg School of Medicine and Northwestern Memorial Hospital and Director of Center for Rare Neurological Diseases at Feinberg. Previously, he spent 20 years at Harvard Medical School completing his research training followed by a neurology residency and fellowship in movement disorders at Massachusetts General Hospital (MGH) and Brigham  and Womens Hospital. He then served on the clinical and research faculty in the Department of Neurology at MGH and Harvard Medical School. 




Joseph Mazzulli, Ph.D., Scientific Founder. Joseph is assistant professor of neurology at the Northwestern University Feinberg School of Medicine. The major focus of his laboratory is to define mechanistic similarities between rare genetic lysosomal diseases and more common neurodegenerative disorders that are characterized by the accumulation of amyloid proteins, such as Parkinson's and Alzheimer's diseases.





Henri Termeer, Founder. Henri is the former Chairman, President and CEO of Genzyme Corp. where he served for over 25 years, creating an industry icon. Genzyme was named a Fortune 500 company in 2010 and was acquired by Sanofi in a more than $20 billion transaction in April 2011. He now serves on many Boards, including the MIT Corporation, the Massachusetts General Hospital, Partners HealthCare, Fellows of Harvard Medical the Biotechnology Industry Organization (BIO).  He also serves on the Boards of Abiomed, Inc., AVEO Pharmaceuticals, Verastem, Inc., and Moderna Therapeutics.





Bob Carpenter, Founder and Chairman of the Board. Bob is a successful entrepreneur, having founded and lead several companies, such as VacTex Inc. (acquired by Aquila Biopharmaceuticals in 1998), and GelTex Pharmaceuticals and Integrated Genetics, both merged with Genzyme. Following the merger of IG, Bob was EVP, CEO and chairman of Genzyme’s subsidiary IG Laboratories till 1991, and served as a Director on Genzyme’s Board until its acquisition. He’s currently Chairman of Hydra Biosciences.




Peter Wirth, J.D., Founder. During his 15-year tenure at Genzyme, he was a senior executive with responsibility for its legal, corporate development and risk management functions and its molecular oncology and polymer research divisions. He is currently Chairman of FORMA Therapeutics, a discovery-stage oncology company and is a member of the Board of Directors at Synageva.  Before joining Genzyme, he practiced law at Palmer & Dodge in Boston.





Edmund Sybertz, Ph.D., Founder.Ted Sybertz, Ph.D., held various research leadership positions at Schering Plough, Geltex and Genzyme, focusing on cardiovascular and CNS diseases. At Genzyme, he played a leadership role in discovery and preclinical development of the glucosyl ceramide synthesis inhibitor, eliglustat. He has been associated with the discovery and introduction of over 20 molecules into clinical development, six of which were ultimately approved.





Kees Been, Founder, President and CEO. Kees was formerly the President and CEO of EnVivo Pharmaceuticals where he ledEnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at Biogen where he directed the Oncology Business Unit which was sold to Idec, and, as Senior Vice President of Business Development.

 Company Founders